|Grant Number:||5R01CA134444-04 Interpret this number|
|Primary Investigator:||Rosenstein, Barry|
|Organization:||Icahn School Of Medicine At Mount Sinai|
|Project Title:||Genome-Wide Study to Identify Snps and Cnps Associated with Radiation Injury|
A subgroup of prostate cancer patients treated with brachytherapy experience radiation-induced injury manifested as either urinary morbidity, proctitis or erectile dysfunction (ED). Results have been obtained from a series of studies suggestive of a genetic basis for clinical radiosensitivity and it has been hypothesized that many patients who exhibit normal tissue radiation toxicity harbor specific single nucleotide polymorphisms (SNPs) and copy number polymorphisms (CNPs) associated with a susceptibility for the development of adverse effects resulting from a radiation treatment for prostate cancer. However, the research performed to date has been restricted to genotyping only a limited number of SNPs in a small group of candidate genes. In recognition of our inadequate understanding of the pathways involved in the development of radiation-induced urinary morbidity, proctitis and ED, as well as the incomplete knowledge of the spectrum of genes/proteins involved in the development of these forms of radiation toxicity, it is likely that we have failed to identify many of the SNPs and CNPs that are associated with the development of these manifestations of radiation injury. Therefore, we are proposing a new and innovative strategy to achieve this goal in which a genome wide association study will be performed to discover a more complete spectrum of the SNPs and CNPs (and genes) that are associated with clinical radiosensitivity. This will be a case-control study in which each prostate cancer patient that develops either urinary morbidity, proctitis or ED will be matched on age, race, stage, date of diagnosis and dosimetric parameters, with an appropriate control patient who did not develop that form of radiation injury. There will be 200 cases and 200 controls for each form of radiation injury in this study. Half of the subjects will first be screened for SNPs and CNPs using the Affymetrix 6.0 SNP array. The type I error (a) for rejection of the null hypothesis will be set at 0.0001. Therefore, depending on the minor allele frequency, we will be able to identify SNPs and CNPs whose genome relative risks (GRRs) for the development of each form of radiation induced injury is greater than approximately 2.5. Although this is a relatively modest number of subjects for a genome wide association study, therefore enabling identification of SNPs or CNPs only with relatively high GRRs, it is important to note that only SNPs and CNPs with GRRs greater than roughly 2.5 will likely be of useful predictive value in the actual clinical setting considering the dosimetric uncertainties associated with a standard radiotherapy treatment. A second phase validation study will be performed with a separate replication set comprising the other half of the subjects selected for this project using an a of 0.01, which should eliminate virtually all false positives identified in the initial phase. Finally, we will perform comprehensive SNP screening for all subjects of the DNA region surrounding every SNP that proves positively associated with each form of radiation injury in the replication set of subjects in order to genotype all SNPs in a haplotype block.
Radiogenomics: radiobiology enters the era of big data and team science.
Authors: Rosenstein BS, West CM, Bentzen SM, Alsner J, Andreassen CN, Azria D, Barnett GC, Baumann M, Burnet N, Chang-Claude J, Chuang EY, Coles CE, Dekker A, De Ruyck K, De Ruysscher D, Drumea K, Dunning AM, Easton D, Eeles R, Fachal L, Gutiérrez-Enríquez S, Haustermans K, Henríquez-Hernández LA, Imai T, Jones GD, Kerns SL, Liao Z, Onel K, Ostrer H, Parliament M, Pharoah PD, Rebbeck TR, Talbot CJ, Thierens H, Vega A, Witte JS, Wong P, Zenhausern F, Radiogenomics Consortium
Source: Int J Radiat Oncol Biol Phys, 2014 Jul 15;89(4), p. 709-13.
A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity.
Authors: Barnett GC, Thompson D, Fachal L, Kerns S, Talbot C, Elliott RM, Dorling L, Coles CE, Dearnaley DP, Rosenstein BS, Vega A, Symonds P, Yarnold J, Baynes C, Michailidou K, Dennis J, Tyrer JP, Wilkinson JS, Gómez-Caamaño A, Tanteles GA, Platte R, Mayes R, Conroy D, Maranian M, Luccarini C, Gulliford SL, Sydes MR, Hall E, Haviland J, Misra V, Titley J, Bentzen SM, Pharoah PD, Burnet NG, Dunning AM, West CM
Source: Radiother Oncol, 2014 May;111(2), p. 178-85.
EPub date: 2014 Apr 28.
Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy.
Authors: Kerns SL, Ostrer H, Rosenstein BS
Source: Cancer Discov, 2014 Feb;4(2), p. 155-65.
EPub date: 2014 Jan 17.
STROGAR - STrengthening the Reporting Of Genetic Association studies in Radiogenomics.
Authors: Kerns SL, de Ruysscher D, Andreassen CN, Azria D, Barnett GC, Chang-Claude J, Davidson S, Deasy JO, Dunning AM, Ostrer H, Rosenstein BS, West CM, Bentzen SM
Source: Radiother Oncol, 2014 Jan;110(1), p. 182-8.
EPub date: 2013 Aug 27.
Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer.
Authors: Kerns SL, Stock RG, Stone NN, Blacksburg SR, Rath L, Vega A, Fachal L, Gómez-Caamaño A, De Ruysscher D, Lammering G, Parliament M, Blackshaw M, Sia M, Cesaretti J, Terk M, Hixson R, Rosenstein BS, Ostrer H
Source: Radiother Oncol, 2013 Jun;107(3), p. 372-6.
EPub date: 2013 May 26.
A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of urinary symptoms after radiotherapy for prostate cancer.
Authors: Kerns SL, Stone NN, Stock RG, Rath L, Ostrer H, Rosenstein BS
Source: J Urol, 2013 Jul;190(1), p. 102-8.
EPub date: 2013 Feb 1.
Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity.
Authors: Barnett GC, Elliott RM, Alsner J, Andreassen CN, Abdelhay O, Burnet NG, Chang-Claude J, Coles CE, Gutiérrez-Enríquez S, Fuentes-Raspall MJ, Alonso-Muñoz MC, Kerns S, Raabe A, Symonds RP, Seibold P, Talbot CJ, Wenz F, Wilkinson J, Yarnold J, Dunning AM, Rosenstein BS, West CM, Bentzen SM
Source: Radiother Oncol, 2012 Dec;105(3), p. 289-95.
EPub date: 2012 Nov 28.
A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of erectile dysfunction following radiation therapy for prostate cancer.
Authors: Kerns SL, Stock R, Stone N, Buckstein M, Shao Y, Campbell C, Rath L, De Ruysscher D, Lammering G, Hixson R, Cesaretti J, Terk M, Ostrer H, Rosenstein BS
Source: Int J Radiat Oncol Biol Phys, 2013 Jan 1;85(1), p. e21-8.
EPub date: 2012 Sep 26.
Genome-wide association studies and prediction of normal tissue toxicity.
Authors: West CM, Dunning AM, Rosenstein BS
Source: Semin Radiat Oncol, 2012 Apr;22(2), p. 91-9.
Predicting toxicity from radiation therapy--it's genetic, right?
Authors: Kelsey CR, Rosenstein BS, Marks LB
Source: Cancer, 2012 Jul 15;118(14), p. 3450-4.
EPub date: 2011 Dec 5.
Identification of SNPs associated with susceptibility for development of adverse reactions to radiotherapy.
Authors: Rosenstein BS
Source: Pharmacogenomics, 2011 Feb;12(2), p. 267-75.
Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer.
Authors: Kerns SL, Ostrer H, Stock R, Li W, Moore J, Pearlman A, Campbell C, Shao Y, Stone N, Kusnetz L, Rosenstein BS
Source: Int J Radiat Oncol Biol Phys, 2010 Dec 1;78(5), p. 1292-300.